Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops

Abstract excerpt

The emergence of low molecular weight kinase inhibitors as "targeted" drugs has led to remarkable advances in the treatment of cancer patients. The clinical benefits of these tumor therapies, however, vary widely in patient populations and with duration of treatment. Intrinsic and acquired resistance against such drugs limits their efficacy. In addition to the well studied mechanisms of resistance based upon drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to Melanoma and MAPK Pathways
• Share to PI3K/AKT/mTOR signaling in cancer